Brief: Syndax Announces Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Selected as Late-Breaking Presentation
21/11/2023 14:08
Nov 21 (Reuters) - Syndax Pharmaceuticals Inc SNDX.O :
* SYNDAX ANNOUNCES DATA FROM PIVOTAL AUGMENT-101 TRIAL OF
REVUMENIB IN RELAPSED/REFRACTORY KMT2AR ACUTE LEUKEMIA SELECTED
AS LATE-BREAKING PRESENTATION AT THE 65TH ASH ANNUAL MEETING
Source text for Eikon: ID:nPn5XvwMYa
Further company coverage: SNDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Syndax Pharmaceuticals
See all newsBrief: Syndax Announces Topline Results From Maxpire Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis
Syndax says mid-stage trial of lung disease treatment fails main goal, ends development
Syndax Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Syndax Q2 revenue jumps 92% on Revuforj, Niktimvo demand
Brief: Syndax Pharmaceuticals Q2 Operating Income USD -39.995 Million